EPM News Update
Penn Pharma has appointed Kat Jones as Director, Marketing and Commercial Operations. Att the company’s Tredegar offices in South Wales, UK, Jones will strengthen the executive board in relation to marketing, communications and commercial planning. She joins at a crucial time for Penn Pharma as it gears up ready for the launch of its brand new Contained Manufacturing operation situated at the same site.
With over eighteen years’ experience in various senior sales and marketing roles, Jones brings a wealth of expertise to reinvigorate Penn Pharma’s brand image and route to market to both large and small pharmaceutical companies. Previously working on a consultancy basis to other leading healthcare brands, Jones has also held positions at Bupa where she was Commercial Director, Archimedes where she was Sales Director as well as senior roles within Pfizer Marketing and Aventis.
A brand new role on the Penn Pharma executive board, Jones’ position as Director for Marketing and Commercial Operations has been created as the company looks to strengthen its appeal to international companies in the pharmaceutical sector. In particular, Jones will be tasked with marketing the new Contained Manufacturing facility in South Wales to clients internationally and continue to build on Penn’s heritage.
Jones will report to Chief Executive Dr. Richard Yarwood, who is delighted to have her on board. “2013 is going to be a significant year for us at Penn Pharma and so it is vital we have the right components in place to support the demand for both our existing and new services,” he said.
“Kat has the perfect attitude, experience and approach to making sure our client base continues to receive the expertise and service they require, whilst making sure the world knows about our new contained facility and I am confident that Kat is just the person to help us make that known to the industry and really put Penn Pharma on the map.”
On joining the team, Jones said: “The next six to twelve months are certainly going to be a period of change for Penn Pharma and I feel privileged to be a part of this. Having come from a different side of pharmaceuticals, I am hoping to bring a fresh approach to communications and commercial operations that will give the business a new look and feel.”
Penn Pharma has a wealth of experience in successfully providing an integrated range of services for the development, manufacture and distribution of medicinal products to the global pharmaceutical market. The company’s new containment facility includes equipment and systems for the development, clinical and commercial supply of tablets and capsules containing highly potent actives.
Penn Pharma Ltd, +44 1495 711 222, www.pennpharm.com.